Abbott's Freestyle Libre 2 and 3 are the first CGMs to receive FDA clearance for use during imaging tests like X-rays, CT ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Abbott on Nov. 18 held a ceremony to celebrate the official opening of a state-of-the-art manufacturing facility in Kilkenny, ...

Abbott (NYSE:ABT) today announced a significant milestone abroad with the opening of a new manufacturing facility in Ireland.

FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

We are excited to work with Abbott to empower healthcare providers and people living with diabetes to see data from their ...

We are excited to work with Abbott to empower healthcare providers and people living with diabetes to see data from their FreeStyle Libre sensors on Tidepool and Tidepool+,” said Brandon Arbiter ...

FreeStyle Libre 2 sensors will be phased out in the UK by the end of August 2025, meaning that people living with diabetes who use the sensors will need to transition to using FreeStyle Libre 2 Plus ...